Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Anesthesia
  • Anesthesia News
  • Etomidate analogue...

Etomidate analogue promising agent for general anesthesia induction with rapid recovery profile: Study

Dr  Monish  RautWritten by Dr Monish Raut Published On 2025-02-13T20:15:24+05:30  |  Updated On 13 Feb 2025 8:15 PM IST
Etomidate  analogue promising agent for general anesthesia induction with rapid recovery profile: Study
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

Recently published study focused on the evaluation of a novel etomidate analogue, methoxyethyl etomidate hydrochloride (ET-26), in healthy volunteers to assess its safety, tolerability, hypnotic effects, and pharmacokinetics. Etomidate, an intravenous general anesthetic, is known for cardiovascular stability but has limitations such as adrenocortical suppression. Efforts have been made to develop etomidate analogues that preserve its benefits while addressing its drawbacks. ET-26 was designed to maintain anesthesia properties while reducing adrenocortical suppression through a modified ester side chain.

Phase 1 Clinical Trial of ET-26

The study, a phase 1 single-center trial, included two stages: a dose-escalation study (stage 1a) and a head-to-head study (stage 1b) comparing ET-26 with etomidate. The primary endpoints were safety and tolerability, while secondary endpoints included pharmacokinetic and pharmacodynamic properties. Healthy participants aged 18-45 were enrolled, and ET-26 was administered intravenously at escalating doses.

Safety and Tolerability of ET-26

Safety assessments revealed that ET-26 was well-tolerated, with dose-dependent hypnotic effects observed. Adverse events were mainly mild, including bradycardia, myoclonus, and injection site pain. Hypnotic effects were dose-dependent, with ET-26 producing rapid-onset and short-lasting unconsciousness. The onset time and duration of unconsciousness increased with higher doses. ET-26 exhibited a more favorable adrenocortical response compared to etomidate, with less suppression observed. Pharmacokinetic evaluations showed a linear profile for ET-26, fitting a two-compartment model. Plasma concentrations of ET-26 and its major metabolite increased with dose escalation. The study also evaluated the dose-effect relationship, indicating increasing incidence of sedation, unconsciousness, and adrenal insufficiency with higher doses of ET-26. The recommended dose for unconsciousness was determined to be 0.8 mg/kg, with a maximum tolerable dose of 2.8 mg/kg.

Promising Aspects of ET-26

The results highlighted ET-26 as a promising agent for general anesthesia induction, with a wide therapeutic window and rapid recovery profile. The analogue demonstrated better adrenocortical function preservation compared to etomidate, with a more favorable pharmacokinetic profile. Myoclonus observed with ET-26 was transient and spontaneously resolved, distinguishing it from the involuntary muscle movements associated with etomidate analogues like ABP-700. The study provided valuable insights into the safety, clinical effects, and pharmacokinetics of ET-26 in healthy volunteers, suggesting its potential as a novel anesthetic agent with improved safety profile and hypnotic efficacy.

Key Points

- Evaluation focused on a novel etomidate analogue, ET-26, designed to maintain anesthesia properties while reducing adrenocortical suppression through a modified ester side chain.

- Phase 1 clinical trial of ET-26, a single-center trial including dose-escalation and head-to-head studies with etomidate, showed well-tolerated, dose-dependent hypnotic effects with mild adverse events such as bradycardia, myoclonus, and injection site pain.

- Safety and tolerability assessments revealed ET-26 produced rapid-onset and short-lasting unconsciousness in a dose-dependent manner, with a more favorable adrenocortical response compared to etomidate.

- Pharmacokinetic evaluations showed linear profile and two-compartment model fitting for ET-26, with plasma concentrations and metabolite levels increasing with dose escalation, determining a recommended dose of 0.8 mg/kg for unconsciousness and maximum tolerable dose of 2.8 mg/kg.

- Promising aspects of ET-26 include wide therapeutic window and rapid recovery profile for general anesthesia induction, better preservation of adrenocortical function, and transient myoclonus with spontaneous resolution, suggesting potential as a novel anesthetic agent with improved safety and hypnotic efficacy.

- Study provides insights into safety, clinical effects, and pharmacokinetics of ET-26 in healthy volunteers, indicating its potential as a safer and more effective alternative to etomidate for general anesthesia induction.

Reference –

J. Sneyd & Beatrijs I. Valk (2024). Etomidate And Its Derivatives: Time To Say Goodbye?. *British Journal Of Anaesthesia*, 134 1, 11-13 . https://doi.org/10.1016/j.bja.2024.09.011.

adrenal insufficiencyetomidate analoguesintravenous anaestheticpharmacokineticsphase 1 clinical trial
Dr  Monish  Raut
Dr Monish Raut

    MBBS, MD (Anaesthesiology), FNB (Cardiac Anaesthesiology)

    Dr Monish Raut is a practicing Cardiac Anesthesiologist. He completed his MBBS at Government Medical College, Nagpur, and pursued his MD in Anesthesiology at BJ Medical College, Pune. Further specializing in Cardiac Anesthesiology, Dr Raut earned his FNB in Cardiac Anesthesiology from Sir Ganga Ram Hospital, Delhi.

    Show Full Article
    Next Story

    Editorial

    Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

    Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    View All

    Journal Club Today

    Study Reveals Why Your Immune System Works Better in Daylight

    Study Reveals Why Your Immune System Works Better in Daylight

    View All

    Health News Today

    Health Bulletin 30/May/2025

    Health Bulletin 30/May/2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok